Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Dispensing Point Services Should Continue: Mr Arai of Sugi HD
January 12, 2012
- Kyowa Kirin President Matsuda Aims for Global Presence in Biosimilar Business
January 11, 2012
- DSP to Change Brand Name of Almarl to Avoid Confusion
January 11, 2012
- Kyowa Hakko Kirin to Develop Expert MRs to Boost Cancer Field
January 11, 2012
- Nipro to Set Up Pharmaceutical Plant in Vietnam for Contract Manufacturing of Generics
January 11, 2012
- Interprotein, Takeda to Collaborate on Molecular Designing of PPI Modulators
January 11, 2012
- Observation Period Ended in PII/III Trial of Elpamotide: OncoTherapy
January 11, 2012
- DWTI’s Antiplatelet Agent Enters Late PII Stage
January 11, 2012
- Bayer Submits Rivaroxaban in EU, US for Add’l Indication
January 11, 2012
- Top Managements of Pharmaceutical Companies Express Complaints for Additional Price Cut for Long-Listed Drugs
January 10, 2012
- Bayer Yakuhin to Promote Long-Listed Products Without Mediation by MRs
January 10, 2012
- Bayer Yakuhin President Guth Says Marketing Success of 2 Strategic Products Key Focus
January 10, 2012
- Toho HD Chairman Matsutani Showed Enthusiasm for 3rd Round of Distribution Improvement Talks
January 10, 2012
- Takeda and Osaka Univ. Establish Joint Research Chair for Nano-particle Vaccines
January 10, 2012
- Astellas Terminates License Agreement for VIBATIV Injection
January 10, 2012
- Asahi Kasei Pharma Launches Flivas in South Korea through Dong-A
January 10, 2012
- Pharmacist Survey Shows Meiji Seika Pharma Rise to 3rd Rank for “Memorable” MRs
January 6, 2012
- Deutsche Securities Report Says Patent Cliff Concerns Scarce for MTPC
January 6, 2012
- AZ President Hudson Says Development of Japanese Leaders One of Key Company Issues
January 6, 2012
- AZ to Utilize E-detailing, Optimize According to Product
January 6, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…